TGI

Overviews of genetics of hereditary breast cancer and therapeutics:

Hereditary breast cancer: new genetic developments, new therapeutic avenues
Campeau PM, Foulkes WD, Tischkowitz MD

http://www.ncbi.nlm.nih.gov/pubmed/18575892

Breast cancer genes: therapeutic strategies
Holt JT

http://www.ncbi.nlm.nih.gov/pubmed/9616738

Personalized medicine: PARP inhibitors and BRCA1/BRCA2:

Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity
Auman JT, McLeod HL

http://www.ncbi.nlm.nih.gov/pubmed/18559613

Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics
Rubinstein WS

http://www.ncbi.nlm.nih.gov/pubmed/17624601

PARP inhibitor development for systemic cancer targeting
Zaremba T, Curtin NJ

http://www.ncbi.nlm.nih.gov/pubmed/17896912

Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007: 3529
© 2007 American Society of Clinical Oncology

First in human phase I pharmakinetic (PK) and phramacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers.
Yap TA, Boss DS, Fong PC, Roelvink M, Tutt A, Carmichael J, O’Connor MJ, Kaye SB, Shellens JH, de Bono JS

http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/3529

N Engl J Med. 2009 Jul 9;361(2):123-34. Epub 2009 Jun 24.Related Articles, Links Comment in: N Engl J Med. 2009 Jul 9;361(2):189-91. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Drug Development Unit, Royal Marsden National Health Service Foundation Trust and the Institute of Cancer Research, Sutton, Surrey, United Kingdom.

http://content.nejm.org/cgi/content/abstract/361/2/123

Cancer Res. 2009 May 1;69(9):3850-5. Epub 2009 Apr 21. Links Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, Douglas-Jones A, Smith GC, Martin NM, O'Connor M, Clarke AR. Department of Genetics, School of Biosciences, Cardiff University, Cardiff, United Kingdom.

http://cancerres.aacrjournals.org/cgi/content/abstract/69/9/3850